{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:09:14Z","timestamp":1793257754930,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,27]]},"DOI":"10.1097\/01.tp.0000121763.44137.fa","type":"journal-article","created":{"date-parts":[[2004,5,18]],"date-time":"2004-05-18T08:00:35Z","timestamp":1084867235000},"page":"1545-1550","source":"Crossref","is-referenced-by-count":51,"title":["RESOURCE USE AND TREATMENT COSTS AFTER KIDNEY TRANSPLANTATION: IMPACT OF DEMOGRAPHIC FACTORS, COMORBIDITIES, AND COMPLICATIONS"],"prefix":"10.1097","volume":"77","author":[{"given":"Ernst-G\u00fcnther","family":"Hagenmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"H\u00e4ussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Grannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kal\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kilburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Nashan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1093\/ndt\/14.10.2332","article-title":"Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries.","volume":"10","author":"Berthoux","year":"1999","journal-title":"Nephrol Dial Transpl"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1017\/S026646230000876X","article-title":"Cost effectiveness studies of renal transplantation.","volume":"11","author":"Karlberg","year":"1995","journal-title":"J Tech Assess Health Care"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States 1988 to 1996.","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00041552-199811000-00006","article-title":"New immunosuppressive strategies.","volume":"7","author":"Keown","year":"1998","journal-title":"Curr Opin Nephrol Hypertension"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00007890-199606150-00006","article-title":"Determinants of graft survival after renal transplantation.","volume":"61","author":"Pirsch","year":"1996","journal-title":"Transplantation"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/00007890-200010150-00018","article-title":"Increased impact of acute rejection on chronic allograft failure in recent era.","volume":"70","author":"Meier-Kriesche","year":"2000","journal-title":"Transplantation"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/00007890-200106150-00015","article-title":"Economic analysis of basiliximab in renal transplantation.","volume":"71","author":"Keown","year":"2001","journal-title":"Transplantation"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.V8101592","article-title":"The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. US Renal Transplant Mycophenolate Mofetil Study Group.","volume":"8","author":"Sullivan","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients.","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02966500","article-title":"Cost measurement in the economic evaluation in health care: cost of acute inpatient care at the university hospital of Ulm. Z. f.","volume":"7","author":"Klose","year":"1999","journal-title":"Gesundheitswiss"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.1996.307","article-title":"A study of the quality of life and cost utility of renal transplantation.","volume":"50","author":"Laupacis","year":"1996","journal-title":"Kidney Int"},{"issue":"7","key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00007890-200110150-00014","article-title":"Simulect Phase IV Study Group: a randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.","volume":"72","author":"Ponticelli","year":"2001","journal-title":"Transplantation"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/00007890-199911150-00017","article-title":"Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome.","volume":"68","author":"Ishikawa","year":"1999","journal-title":"Transplantation"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/00007890-199910270-00023","article-title":"Features of acute rejection that increase risk for chronic rejection.","volume":"68","author":"Humar","year":"1999","journal-title":"Transplantation"},{"key":"R22-12-20210129","first-page":"441","article-title":"Does subclinical rejection contribute to chronic rejection in renal transplant patients Clin T","volume":"13","author":"Rush","year":"1999","journal-title":"ransplant"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1432-2277.2000.tb01019.x","article-title":"Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort-study with case-control analysis.","volume":"13","author":"Toupance","year":"2000","journal-title":"Transpl Int"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/00007890-199306000-00013","article-title":"The cost impact of cytomegalovirus disease in renal transplant recipients.","volume":"55","author":"McCarthy","year":"1993","journal-title":"Transplantation"},{"issue":"12","key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/00007890-199812270-00022","article-title":"Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection.","volume":"66","author":"Shoskes","year":"1998","journal-title":"Transplantation"},{"key":"R27-12-20210129","first-page":"1304","article-title":"Economic impact of delayed graft function.","volume":"23","author":"Almond","year":"1991","journal-title":"Transpl Proc"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1399-0012.1997.tb00816.x","article-title":"Risk factors for prolonged hospitalization after kidney transplants.","volume":"11","author":"Matas","year":"1997","journal-title":"Clin Transpl"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1034\/j.1399-0012.2000.140506.x","article-title":"A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.","volume":"14","author":"Lorber","year":"2000","journal-title":"Clin Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007890-200405270-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T19:17:07Z","timestamp":1734376627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-200405270-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,27]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000121763.44137.fa","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5,27]]}}}